© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
July 14, 2022
“The real-world data suggest that the use of tumor sequencing is definitely suboptimal,” says Pedro C. Barata, MD, MSc.
July 06, 2022
In this interview, Simpa Salami, MD, MPH, discusses the development of urinary biomarkers in prostate cancer detection.
“Our ability to develop innovative technologies and approaches continues to evolve. We have newer molecular profiling techniques that are being applied to urine at the moment,” says Simpa Salami, MD, MPH.
July 02, 2022
In a recent study, investigators administered a small-molecule inhibitor called MYCi975 to prostate cancer cells, examining the effects on gene expression throughout the human genome.
June 16, 2022
Robert E. Brannigan, MD, discusses which men with infertility issues should receive genetic testing.
June 08, 2022
Rao is an investigator on the ongoing phase 3 CASPAR trial exploring the AR pathway inhibitor enzalutamide combined with the PARP inhibitor rucaparib in patients with mCRPC.
May 27, 2022
Fear of discrimination has downstream effects on health care.
May 19, 2022
TROP-2 and Nectin-4, surface cell targets of sacituzumab govitecan and enfortumab vedotin, respectively, are highly expressed in variant histology bladder cancer.
May 16, 2022
“We really try to be careful about testing, especially when it's a potential burden of costs on the patient. What we really look at is where it's going to have an impact,” says Stephen J. Savage, MD.
May 02, 2022
The study specifically examined this precision medicine pathway in the context of frontline treatment selection between nivolumab with or without ipilimumab and a VEGFR tyrosine kinase inhibitor.